JPMorgan Chase & Co. Buys 28,606 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)

JPMorgan Chase & Co. increased its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 74.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,138 shares of the biopharmaceutical company’s stock after buying an additional 28,606 shares during the quarter. JPMorgan Chase & Co. owned 0.15% of Abeona Therapeutics worth $424,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Jane Street Group LLC acquired a new stake in shares of Abeona Therapeutics during the third quarter worth approximately $84,000. Charles Schwab Investment Management Inc. acquired a new stake in Abeona Therapeutics during the 3rd quarter valued at $151,000. XTX Topco Ltd acquired a new stake in Abeona Therapeutics during the 3rd quarter valued at $160,000. GSA Capital Partners LLP raised its position in Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after purchasing an additional 33,831 shares during the last quarter. Finally, Citigroup Inc. boosted its stake in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ABEO. StockNews.com lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Shares of NASDAQ:ABEO opened at $5.45 on Thursday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. Abeona Therapeutics Inc has a 1-year low of $3.05 and a 1-year high of $9.01. The stock has a market capitalization of $236.92 million, a P/E ratio of -2.03 and a beta of 1.46. The business has a 50-day moving average price of $5.74 and a two-hundred day moving average price of $5.73.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.